Rationale and Design of a Randomized Study Comparing the Watchman FLX Device to DOACs in Patients with Atrial Fibrillation.

[1]  M. Price,et al.  Comparative Safety of Transcatheter LAAO With the First-Generation Watchman and Next-Generation Watchman FLX Devices. , 2022, JACC. Cardiovascular interventions.

[2]  S. Willems,et al.  The ALSTER-FLX Registry: 3-month outcomes following left atrial appendage occlusion employing a next-generation device, a matched-pair-analysis to EWOLUTION. , 2022, Heart rhythm.

[3]  P. Neužil,et al.  Left Atrial Appendage Closure versus Non-Warfarin Oral Anticoagulation in Atrial Fibrillation: 4-Year Outcomes of PRAGUE-17. , 2021, Journal of the American College of Cardiology.

[4]  V. Reddy,et al.  Primary Outcome Evaluation of a Next-Generation Left Atrial Appendage Closure Device , 2021, Circulation.

[5]  H. Diener,et al.  Clinical Outcomes Associated With Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation. , 2021, JACC. Cardiovascular interventions.

[6]  Jeroen J. Bax,et al.  2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS). , 2020, European heart journal.

[7]  P. Neužil,et al.  Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. , 2020, Journal of the American College of Cardiology.

[8]  S. Windecker,et al.  Left atrial appendage closure versus medical therapy for atrial fibrillation: the APPLY study. , 2020, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[9]  D. Delurgio,et al.  Long-Term Safety and Efficacy in Continued Access Left Atrial Appendage Closure Registries. , 2019, Journal of the American College of Cardiology.

[10]  P. Noseworthy,et al.  Stroke Prevention in Nonvalvular Atrial Fibrillation: A Stakeholder Perspective. , 2018, Journal of the American College of Cardiology.

[11]  D. Holmes,et al.  Burden of Atrial Fibrillation-Associated Ischemic Stroke in the United States. , 2018, JACC. Clinical electrophysiology.

[12]  Saibal Kar,et al.  5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. , 2017, Journal of the American College of Cardiology.

[13]  C. Torp‐Pedersen,et al.  Adherence with oral anticoagulation in non-valvular atrial fibrillation: a comparison of vitamin K antagonists and non-vitamin K antagonists , 2017, European heart journal. Cardiovascular pharmacotherapy.

[14]  Dhanunjaya R. Lakkireddy,et al.  Percutaneous left atrial appendage occlusion: the Munich consensus document on definitions, endpoints and data collection requirements for clinical studies. , 2016, EuroIntervention : journal of EuroPCR in collaboration with the Working Group on Interventional Cardiology of the European Society of Cardiology.

[15]  G. Lip,et al.  Antithrombotic and Anticoagulant Therapy for Atrial Fibrillation. , 2016, Heart failure clinics.

[16]  S. Schulman,et al.  Definition of clinically relevant non‐major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non‐surgical patients: communication from the SSC of the ISTH , 2015, Journal of thrombosis and haemostasis : JTH.

[17]  Saibal Kar,et al.  Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. , 2014, JAMA.

[18]  M. Price,et al.  Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. , 2014, Journal of the American College of Cardiology.

[19]  Alexander Parkhomenko,et al.  Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials , 2014, The Lancet.

[20]  E. Antman,et al.  Edoxaban versus warfarin in patients with atrial fibrillation. , 2013, The New England journal of medicine.

[21]  D. Atar,et al.  Mass screening for silent atrial fibrillation in high risk patients - preliminary results from the STROKESTOP trial , 2013 .

[22]  G. Breithardt,et al.  Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. , 2011, The New England journal of medicine.

[23]  S. Yusuf,et al.  Dabigatran versus warfarin in patients with atrial fibrillation. , 2009, The New England journal of medicine.

[24]  Maurice Buchbinder,et al.  Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial , 2009, The Lancet.

[25]  W. Brannath,et al.  A graphical approach to sequentially rejective multiple test procedures , 2009, Statistics in medicine.

[26]  D. Singer,et al.  Death and disability from warfarin-associated intracranial and extracranial hemorrhages. , 2007, The American journal of medicine.

[27]  M. Aguilar,et al.  Meta-analysis: Antithrombotic Therapy to Prevent Stroke in Patients Who Have Nonvalvular Atrial Fibrillation , 2007, Annals of Internal Medicine.

[28]  S. Schulman,et al.  Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non‐surgical patients , 2005, Journal of thrombosis and haemostasis : JTH.